Akero Therapeutics, Inc.
AKRO
Rankning i aktier
#3731
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Aktiekurs
$54.65
Senast synkroniserad: 2025-12-09
Marknadsvärde
$4.50B
Förändring (1 dag)
0.00%
Förändring (1 år)
1.58%
Land
US
Handel Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Vinst för Akero Therapeutics, Inc. (AKRO)
Vinst i Sep 2025 TTM: $-292.82M
Enligt de senaste finansiella rapporterna från Akero Therapeutics, Inc. är företagets nuvarande vinst $-292.82M. År 2023 hade företaget en vinst på $-151.76M, en minskning jämfört med vinsten år 2022 som var $-112.03M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Akero Therapeutics, Inc. från 2017 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-292.82M | 16.17% |
| 2024 | $-252.06M | 66.09% |
| 2023 | $-151.76M | 35.46% |
| 2022 | $-112.03M | 11.17% |
| 2021 | $-100.78M | 27.23% |
| 2020 | $-79.21M | 81.02% |
| 2019 | $-43.76M | -46.45% |
| 2018 | $-81.71M | 1,690.40% |
| 2017 | $-4.56M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -1,901.41% |
US
|
|
| $-3.09B | 954.23% |
US
|
|
| $-4.02B | 1,271.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -766.16% |
NL
|
